First Trust Advisors LP lowered its stake in shares of Takeda Pharmaceutical Co. (NYSE:TAK – Free Report) by 17.3% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 1,971,074 shares of the company’s stock after selling 411,555 shares during the period. First Trust Advisors LP’s holdings in Takeda Pharmaceutical were worth $36,504,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors have also recently added to or reduced their stakes in the stock. Capital Research Global Investors raised its stake in Takeda Pharmaceutical by 0.6% during the 4th quarter. Capital Research Global Investors now owns 13,486,772 shares of the company’s stock valued at $210,259,000 after acquiring an additional 82,643 shares during the last quarter. UBS Group AG increased its holdings in shares of Takeda Pharmaceutical by 46.4% in the third quarter. UBS Group AG now owns 5,893,969 shares of the company’s stock valued at $86,288,000 after purchasing an additional 1,869,323 shares during the period. Arrowstreet Capital Limited Partnership increased its holdings in shares of Takeda Pharmaceutical by 100.9% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 5,682,847 shares of the company’s stock valued at $88,596,000 after purchasing an additional 2,854,069 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of Takeda Pharmaceutical by 15.0% during the first quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company’s stock worth $79,120,000 after purchasing an additional 692,404 shares during the last quarter. Finally, Van ECK Associates Corp raised its stake in shares of Takeda Pharmaceutical by 98.4% during the fourth quarter. Van ECK Associates Corp now owns 2,305,397 shares of the company’s stock worth $35,941,000 after purchasing an additional 1,143,117 shares during the last quarter. Institutional investors and hedge funds own 9.17% of the company’s stock.
Takeda Pharmaceutical Stock Up 1.2%
TAK opened at $17.45 on Tuesday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.09 and a quick ratio of 0.60. Takeda Pharmaceutical Co. has a 12 month low of $12.99 and a 12 month high of $18.90. The stock has a market capitalization of $55.92 billion, a P/E ratio of 44.75 and a beta of -0.07. The business has a 50 day simple moving average of $16.19 and a 200-day simple moving average of $17.04.
Analyst Ratings Changes
A number of equities analysts recently weighed in on the stock. Zacks Research lowered shares of Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a research report on Monday, June 29th. Weiss Ratings downgraded shares of Takeda Pharmaceutical from a “hold (c)” rating to a “hold (c-)” rating in a research report on Tuesday, June 23rd. Wall Street Zen upgraded shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Finally, Sanford C. Bernstein raised shares of Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a report on Wednesday, April 8th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Takeda Pharmaceutical presently has a consensus rating of “Hold”.
Read Our Latest Stock Analysis on TAK
About Takeda Pharmaceutical
Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.
Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.
Further Reading
- Five stocks we like better than Takeda Pharmaceutical
- AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next
- Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now
- Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There?
- Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight
Want to see what other hedge funds are holding TAK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Takeda Pharmaceutical Co. (NYSE:TAK – Free Report).
Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
